Send to

Choose Destination
See comment in PubMed Commons below
Drugs. 2012 Oct 22;72(15):2033-42. doi: 10.2165/11640860-000000000-00000.

Phentermine and topiramate extended release (Qsymia™): first global approval.

Author information

Adis R&D Insight, Springer Healthcare, Auckland, New Zealand.


Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight loss by decreasing appetite and increasing satiety. The product is also in clinical development for sleep apnoea syndrome and type 2 diabetes mellitus. This article summarizes the milestones in the development of phentermine/topiramate ER leading to this first approval for obesity.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center